小剂量美罗华联合冰冻血浆治疗免疫性血小板减少症  

Adding Fresh Frozen Plasma to Lower Dose Rituximab for the Treatment of Patients with Immunologic Thrombocytopenic

作　　者：孙梅[1] 顾健[1] 何斌[1] 谢晓燕[1] 陈沛帅[1] 马莉[1] 

机构地区：[1]江苏省苏北人民医院扬州市血液学研究所,扬州225001

出　　处：《血栓与止血学》2010年第1期18-20,共3页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的探讨小剂量美罗华联合冰冻血浆治疗免疫性血小板减少症(ITP)的疗效与作用。方法选择2009年6月至11月我院诊断ITP住院患者8例,给予美罗华100 mg.iv.qw×4次,使用前给予冰冻血浆200 ml输注,同服美卓乐24 mg/d,治疗前后检测CD 20表达、血小板数及网织血小板变化。结果3例患者获CR,4例获MR,总反应率87.5%,无不良反应发生。结论小剂量美罗华联合冰冻血浆能有效治疗免疫性血小板减少症。Objective To investigate the effect of lower dose rituximab with fresh trozen plasma on immunologic thrombocytopenic. Methods we observe eight patients with definite dignosis of ITP from June to November in 2009. Rituximab was given as an intravenous infusion at a dose of 100 mg weekly for 4 doses. Giving fresh frozen plasma 200 ml infusion befor injecting rituximab, along with oral Medrol 24 mg per day. To observe CD 20 antigen expression, platelet counts and reticulated platelet counts. Results A complete remission was observed in 3 cases, a minimal response in 4 cases, with an overall response rate of 87.5% , there was no adverse reaction. Conclusions Lower dose rituximab with fresh frozen plasma is beneficial for patients with ITP.

关 键 词：美罗华 冰冻血浆 免疫性 血小板减少症 

分 类 号：R558.2[医药卫生—血液循环系统疾病]